Ya-Ju Tseng

Publications (5)13.59 Total impact

• Article: Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

  Wen-Hsing Lin, John T-A Hsu, Shu-Yi Hsieh, Chiung-Tong Chen, Jen-Shin Song, Shih-Chieh Yen, Tsu Hsu, Cheng-Tai Lu, Chun-Hwa Chen, Ling-Hui Chou, Yung-Ning Yang, Ching-Hui Chiu, Ching-Ping Chen, Ya-Ju Tseng, Kuei-Jung Yen, Ching-Fang Yeh, Yu-Sheng Chao, Teng-Kuang Yeh, Weir-Torn Jiaang
  [show abstract] [hide abstract]
  ABSTRACT: Preclinical investigations and early clinical trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia. However, early clinical data have been underwhelming due to incomplete inhibition of FLT3. We have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors. Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors. Previous studies showed that the sulfonamide 4 and carbamate 5 series were potent and selective FLT3 inhibitors with good in vivo efficacy. Herein, we describe the urea series, which we found to be potent inhibitors of FLT3 and VEGFR2. Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib (2) and ABT-869 (3). In preliminary in vivo toxicity studies of the four most active compounds, 10f was found to be the least toxic. A further in vivo efficacy study demonstrated that 10f achieved complete tumor regression in a higher proportion of MOLM-13 xenograft mice than 4 and 5 (70% vs 10% and 40%). These results show that compound 10f possesses improved pharmacologic and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.
  Bioorganic & medicinal chemistry 04/2013; · 2.82 Impact Factor
• Article: 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

  John T-A Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, Chiung-Tong Chen, Shu-Yi Hsieh, Tsu Hsu, Cheng-Tai Lu, Chun-Hwa Chen, Ling-Hui Chou, Ching-Hui Chiu, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, Wen-Hsing Lin, Weir-Torn Jiaang
  [show abstract] [hide abstract]
  ABSTRACT: A new class of FLT3 inhibitors has been identified based on the 3-phenyl-1H-5-pyrazolylamine scaffold. The structure-activity relationships led to the discovery of two carbamate series, and some potent compounds within these two series exhibited better growth inhibition of FLT3-mutated MOLM-13 cells than FLT3 inhibitors sorafenib (2) and ABT-869 (3). In particular, compound 8d exhibited the ability to regress tumors in mouse xenograft model using MOLM-13 cells.
  Bioorganic & medicinal chemistry letters 07/2012; 22(14):4654-9. · 2.65 Impact Factor
• Article: Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

  Wen-Hsing Lin, Shu-Yi Hsieh, Shih-Chieh Yen, Chiung-Tong Chen, Teng-Kuang Yeh, Tsu Hsu, Cheng-Tai Lu, Ching-Ping Chen, Chun-Wha Chen, Ling-Hui Chou, Yu-Lin Huang, An-Huei Cheng, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, John T-A Hsu, Weir-Torn Jiaang
  [show abstract] [hide abstract]
  ABSTRACT: Preclinical investigations and early clinical trial studies suggest that FLT3 inhibitors offer a viable therapy for acute myeloid leukemia. However, early clinical data for direct FLT3 inhibitors provided only modest results because of the failure to fully inhibit FLT3. We have designed and synthesized a novel class of 3-phenyl-1H-5-pyrazolylamine-derived compounds as FLT3 inhibitors which exhibit potent FLT3 inhibition and high selectivity toward different receptor tyrosine kinases. The structure-activity relationships led to the discovery of two series of FLT3 inhibitors, and some potent compounds within these two series exhibited comparable potency to FLT3 inhibitors sorafenib (3) and ABT-869 (4) in both wt-FLT3 enzyme inhibition and FLT3-ITD inhibition on cell growth (MOLM-13 and MV4;11 cells). In particular, the selected compound 12a exhibited the ability to regress tumors in mouse xenograft models using MOLM-13 and MV4;11 cells.
  Bioorganic & medicinal chemistry 06/2011; 19(14):4173-82. · 2.82 Impact Factor
• Article: (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

  Teng-Kuang Yeh, Ting-Yueh Tsai, Tsu Hsu, Jai-Hong Cheng, Xin Chen, Jen-Shin Song, Horng-Shing Shy, Mei-Chun Chiou, Chia-Hui Chien, Ya-Ju Tseng, Chung-Yu Huang, Kai-Chia Yeh, Yu-Lin Huang, Chih-Hsiang Huang, Yu-Wen Huang, Min-Hsien Wang, Hung-Kuan Tang, Yu-Sheng Chao, Chiung-Tong Chen, Weir-Torn Jiaang
  [show abstract] [hide abstract]
  ABSTRACT: A series of 2-[3-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-based DPP-IV inhibitors with various monocyclic amines were synthesized. The structure-activity relationships (SAR) led to the discovery of potent DPP-IV inhibitors, having IC(50) values of <100 nM with excellent selectivity over the closely related enzymes, DPP-II, DPP8, DPP9 and FAP (IC(50)>20 microM). Of these compounds, the analogues 12a, 12h and 12i exhibited a long-lasting ex vivo DPP-IV inhibition in rats.
  Bioorganic & medicinal chemistry letters 06/2010; 20(12):3596-600. · 2.65 Impact Factor
• Article: Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.

  Ting-Yueh Tsai, Tsu Hsu, Chiung-Tong Chen, Jai-Hong Cheng, Mei-Chun Chiou, Chih-Hsiang Huang, Ya-Ju Tseng, Teng-Kuang Yeh, Chung-Yu Huang, Kai-Chia Yeh, Yu-Wen Huang, Ssu-Hui Wu, Min-Hsien Wang, Xin Chen, Yu-Sheng Chao, Weir-Torn Jiaang
  [show abstract] [hide abstract]
  ABSTRACT: A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have been prepared and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV). The structure-activity relationships (SAR) led to the discovery of potent 3-substituted glutamic acid analogues, providing enhanced chemical stability and excellent selectivity over the closely related enzymes, DPP8, DPP-II and FAP. Compound 13f exhibited the ability to both significantly decrease the glucose excursion and inhibit plasma DPP-IV activity.
  Bioorganic & medicinal chemistry letters 05/2009; 19(7):1908-12. · 2.65 Impact Factor